Filing Details
- Accession Number:
- 0001104659-25-067760
- Form Type:
- 13D Filing
- Publication Date:
- 2025-07-13 20:00:00
- Filed By:
- Fairmount Funds Management LLC
- Company:
- Cogent Biosciences Inc. (NASDAQ:COGT)
- Filing Date:
- 2025-07-14
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 0 | 14,324,918 | 0 | 14,324,918 | 14,324,918 | 9.9% |
| Fairmount Healthcare Fund II GP LLC | 0 | 14,324,918 | 0 | 14,324,918 | 14,324,918 | 9.9% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 7)
|
Cogent Biosciences, Inc. (Name of Issuer) |
Common Stock, $0.001 par value (Title of Class of Securities) |
19240Q201 (CUSIP Number) |
Ms. Erin O'Connor Fairmount Funds Management LLC, 200 Barr Harbor Drive, Suite 400 West Conshohocken, PA, 19428 (267) 262-5300 Ryan A. Murr, Esq. Gibson, Dunn & Crutcher LLP, One Embarcadero Center, Suite 2600 San Francisco, CA, 94111 (415) 393-8373 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
07/10/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 19240Q201 |
| 1 |
Name of reporting person
Fairmount Funds Management LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
 (a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
14,324,918.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IA |
Comment for Type of Reporting Person:
The securities include (a) 9,003,418 shares of common stock, $0.001 par value ("Common Stock"), and (b) 5,325,500 shares of Common Stock issuable upon conversion of approximately 21,302 shares of Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Stock") directly held by Fairmount Healthcare Fund II L.P. ("Fund II"). The securities exclude shares of Common Stock issuable upon conversion of shares of Series A Preferred Stock held directly by Fund II in excess of the beneficial ownership limitation of 9.9%.
Row 13 is based on 139,412,010 shares of Common Stock outstanding, consisting of 113,856,454 shares of Common Stock outstanding as of May 2, 2025 plus 25,555,556 shares of Common Stock sold in the Offering (as defined below).
SCHEDULE 13D
|
| CUSIP No. | 19240Q201 |
| 1 |
Name of reporting person
Fairmount Healthcare Fund II GP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
14,324,918.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
Comment for Type of Reporting Person:
The securities include (a) 9,003,418 shares of Common Stock and (b) 5,325,500 shares of Common Stock issuable upon conversion of approximately 21,302 shares of Series A Preferred Stock directly held by Fund II. The securities exclude shares of Common Stock issuable upon conversion of shares of Series A Preferred Stock held directly by Fund II in excess of the beneficial ownership limitation of 9.9%.
Row 13 is based on 139,412,010 shares of Common Stock outstanding, consisting of 113,856,454 shares of Common Stock outstanding as of May 2, 2025 plus 25,555,556 shares of Common Stock sold in the Offering.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, $0.001 par value | |
| (b) | Name of Issuer:
Cogent Biosciences, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
275 Wyman Street, 3rd Floor, Waltham,
MASSACHUSETTS
, 02451. | |
Item 1 Comment:
This Amendment No. 7 amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission on July 6, 2020, Amendment No. 1 filed on June 21, 2022, Amendment No. 2 filed on June 13, 2023, Amendment No. 3 filed on February 16, 2024, Amendment No. 4 filed on March 27, 2024, Amendment No. 5 filed on April 1, 2024, and Amendment No. 6 filed on June 13, 2024 (as amended, the "Statement" or the "Schedule 13D") by the Reporting Persons with respect to the Common Stock of Cogent Biosciences, Inc. (the "Company"). Unless otherwise defined herein, capitalized terms used in this Amendment No. 7 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. | ||
| Item 2. | Identity and Background | |
| (a) | This Schedule 13D is being filed jointly by (1) Fairmount Funds Management LLC, a Delaware limited liability company and Securities and Exchange Commission ("SEC") registered investment adviser under the Investment Advisers Act of 1940 ("Fairmount Funds Management"); and (2) Fairmount Healthcare Fund II GP LLC, a Delaware limited liability company ("Fairmount GP II") (Fairmount Funds Management and Fairmount GP II, collectively, the "Reporting Persons").
Fairmount Funds Management serves as investment manager for Fund II and may be deemed a beneficial owner for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act") of any securities of the Company held by Fund II. Fund II has delegated to Fairmount Funds Management the sole power to vote and the sole power to dispose of all securities held in Fund II's portfolio, including the shares of Common Stock and Series A Preferred Stock reported herein. Because Fund II has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, Fund II disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. Fairmount Funds Management and Fairmount GP II disclaim beneficial ownership of the securities reported in this Amendment No. 7 other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Amendment No. 7 shall not be deemed an admission that any of Fairmount Funds Management or Fairmount GP II is the beneficial owner of such securities for any other purpose. | |
| (b) | The principal business address of each of the Reporting Persons is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428. | |
| (c) | The principal business of Fairmount Funds Management is to provide discretionary investment management services to qualified investors through its private pooled investment vehicles, including Fund II. Fairmount GP II serves as the general partner to Fund II. Fairmount Funds Management has voting and dispositive power over the Common Stock and Series A Preferred Stock held by the Fund II, which is deemed shared with Fairmount GP II. Fund II does not have the right to acquire voting or dispositive power over the Common Stock or Series A Preferred Stock within sixty-one days. | |
| (d) | During the last five years, neither of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). | |
| (e) | During the last five years, neither of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceedings was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect at such laws. | |
| (f) | Fairmount Funds Management and Fairmount GP II are each a Delaware limited liability company. | |
| Item 3. | Source and Amount of Funds or Other Consideration | |
In aggregate, the Reporting Persons have voting and dispositive power over 25,856,918 shares of Common Stock, which is comprised of (a) 9,003,418 shares of Common Stock and (b) 16,853,500 shares of Common Stock issuable upon conversion of 67,414 shares of Series A Preferred Stock. The conversion of the Series A Preferred Stock is subject to a beneficial ownership limitation of 9.9% of the outstanding Common Stock.
On July 10, 2025, the Fund II purchased a total of 2,777,777 shares of Common Stock of the Company for an aggregate of $24,999,993.00 in an underwritten public offering (the "Offering"). The shares were purchased with working capital. Fairmount Funds Management and Fairmount GP II do not own any shares of Common Stock and Series A Preferred Stock directly but are deemed to beneficially own the shares of Common Stock and Series A Preferred Stock held by Fund II. Fairmount Funds Management and Fairmount GP II disclaim beneficial ownership of such shares of Common Stock and Series A Preferred Stock except to the extent of their pecuniary interest therein. | ||
| Item 4. | Purpose of Transaction | |
Item 4 is hereby amended and supplemented as follows:
Fund II purchased the shares of Common Stock referred to in Item 3 for investment purposes.
Lock-up Agreement
Pursuant to lock-up agreements signed in connection with the Offering, Fund II and each director and officer of the Company agreed with the representatives of the underwriters, subject to specified exceptions, not to directly or indirectly offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of any shares of Common Stock beneficially owned (as such term is used in Rule 13d-3 of the Exchange Act) or any other securities so owned that are convertible into or exercisable or exchangeable for Common Stock; or dispose of any shares of Common Stock, options to acquire shares of Common Stock, or securities exchangeable or exercisable for or convertible into shares of Common Stock currently or hereafter owned either of record or beneficially. This restriction terminates after the close of trading of the Common Stock on and including the 60th day after the date of the prospectus supplement relating to the Offering. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | See Items 7-11 of the cover pages above and Item 2. | |
| (b) | See Items 7-11 of the cover pages above and Item 2. | |
| (c) | The following table lists the Reporting Persons' transaction in Common Stock of the Company that was effected in the sixty day period prior to the filing of this Amendment No. 7:
Transaction Purchaser Date Number of Shares Price Per Share
Purchase Fund II July 10, 2025 2,777,777 $9.00
The Reporting Persons did not effect any transactions in shares of Series A Preferred Stock in the sixty days prior to the filing of this Amendment No. 7. | |
| (d) | Not applicable. | |
| (e) | Not applicable. | |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer | |
Fairmount is entitled to a fee for managing and advising Fund II based upon a percentage of the net asset value of Fund II. | ||
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit No. 99.1 Joint Filing Agreement by and among the Reporting Persons (incorporated by reference to Exhibit 99.1 to the Schedule 13D filed by the Reporting Persons with the SEC on July 10, 2020, File No. 005-90431). | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|